Iota-carrageenan derived nasal spray |
In-vitro inhibition of COVID-19 |
Bansal et al. 2020
|
Carrageenan-derived nasal spray |
2.5% decrease in recurring symptoms |
Koenighofer et al. 2014
|
Carrageenan and fucoidan |
Binds with s-glycoprotein of virus |
Song et al. 2020
|
Iota-carrageenan derived lozenges |
S-glycoprotein denaturation |
Morokutti-Kurz et al. 2017
|
Iota-carrageenan and fucoidan kappa carrageenan |
Prevention of respiratory tract infections |
Grassauer et al. 2008
|
Iota-carrageenan-derived nasal spray |
Upper respiratory tract nasal congestion |
Graf et al. 2018
|
Iota-carrageenan |
The increased recovery rate from COVID-19 infection by 2.4-fold |
Hemilia et al., 2020 |
Lambda-carrageenan |
Prevents viral attachment to receptors of cell surface |
Jang et al. 2020
|
Fucoidan |
Binding of sulfated polysaccharides with s-glycoprotein |
Kwon et al. 2020
|